CEChristopher S. Eickhoff

Christopher S. Eickhoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher S. Eickhoff has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Fredric Hoft

    Affiliations Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University Medical Center, St. Louis, Missouri, United States of America, Department of Molecular Microbiology and Immunology, Saint Louis University Medical Center, St. Louis, Missouri, United States of America

    7 shared publications
  • Anita R. Schnapp

    Department of Internal Medicine, Saint Louis University, Saint Louis, MO 63104

    2 shared publications
  • David A. Ford

    Edward A. Doisy Department of Biochemistry and Molecular Biology and Center for Cardiovascular Research, Saint Louis University School of Medicine, St. Louis, MO, USA

    2 shared publications
  • O. K. Giddings

    Department of Molecular Microbiology and Immunology, Saint Louis University Medical Center, St. Louis, Missouri 63104, USA

    2 shared publications
  • Daniel F. Hoft

    Division of Infectious Diseases, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, USA

    1 shared publication
  • Daniel F. Hoft

    Division of Infectious Diseases, Allergy and Immunology, Department of Internal Medicine, Saint Louis University, St. Louis, MO, United States

    1 shared publication

Latest Publications

  • Homodimeric Granzyme A Opsonizes Mycobacterium tuberculosis and Inhibits Its Intracellular Growth in Human Monocytes via Toll-Like Receptor 4 and CD14

    by Valerio Rasi, Kathleen R Phelps, Keegan R Paulson, Christopher S Eickhoff, Mathivanan Chinnaraj, Nicola Pozzi, Marco Di Gioia, Ivan Zanoni, Shubha Shakya, Haley L Carlson, et al.

    Mycobacterium tuberculosis (Mtb)-specific γ9δ2 T cells secrete GzmA protective against intracellular Mtb growth. However, GzmA enzymatic activity is unnecessary for pathogen inhibition and the mechanisms of GzmA-mediated protection remain unknown. We show GzmA homodimerization is essential for opsonization of mycobacteria, altered uptake into human monocytes and subsequent pathogen clearance within the phagolysosome. While monomeric and homodimeric GzmA bind mycobacteria, only homodimers also bind CD14 and TLR4. Without access to surface expressed CD14 and TLR4, GzmA fails to inhibit intracellular Mtb. Upregulation of Rab11FIP1, was associated with inhibitory activity. Further, GzmA colocalized with and was regulated by protein disulfide isomerase (PDI)A1, which cleaves GzmA homodimers into monomers and prevents Mtb inhibitory activity. These studies identify previously unrecognized role for homodimeric GzmA structure in opsonization, phagocytosis and elimination of Mtb in human monocytes, and highlights PDIA1 as a potential host-directed therapy for prevention and treatment of tuberculosis, a major human disease.


  • Lethal NK-mediated inflammation induced by IL-12 in the absence of polymorphic and nonpolymorphic MHC class I molecules

    by Christopher S. Eickhoff, Anita R. Schnapp, John E. Sagartz, Daniel F. Hoft


  • The Absence of Myocardial Calcium-Independent Phospholipase A 2 γ Results in Impaired Prostaglandin E 2 Production and Decreased Survival in Mice with Acute Trypanosoma cruzi Infection

    by Janhavi Sharma, Christopher S. Eickhoff, Daniel F. Hoft, David A. Ford, Richard W. Gross, Jane McHowat

    Cardiomyopathy is a serious complication of Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi . The parasite often infects cardiac myocytes, causing the release of inflammatory mediators, including eicosanoids. A recent study from our laboratory demonstrated that calcium-independent phospholipase A 2 γ (iPLA 2 γ) accounts for the majority of PLA 2 activity in rabbit ventricular myocytes and is responsible for arachidonic acid (AA) and prostaglandin E 2 (PGE 2 ) release. Thus, we hypothesized that cardiac iPLA 2 γ contributes to eicosanoid production in T. cruzi infection. Inhibition of the isoform iPLA 2 γ or iPLA 2 β, with the R or S enantiomer of bromoenol lactone (BEL), respectively, demonstrated that iPLA 2 γ is the predominant isoform in immortalized mouse cardiac myocytes (HL-1 cells). Stimulation of HL-1 cells with thrombin, a serine protease associated with microthrombus formation in Chagas' disease and a known activator of iPLA 2 , increased AA and PGE 2 release, accompanied by platelet-activating factor (PAF) production. Similarly, T. cruzi infection resulted in increased AA and PGE 2 release over time that was inhibited by pretreatment with ( R )-BEL. Further, T. cruzi -infected iPLA 2 γ-knockout (KO) mice had lower survival rates and increased tissue parasitism compared to wild-type (WT) mice, suggesting that iPLA 2 γ-KO mice were more susceptible to infection than WT mice. A significant increase in iPLA 2 activity was observed in WT mice following infection, whereas iPLA 2 γ-KO mice showed no alteration in cardiac iPLA 2 activity and produced less PGE 2 . In summary, these studies demonstrate that T. cruzi infection activates cardiac myocyte iPLA 2 γ, resulting in increased AA and PGE 2 release, mediators that may be essential for host survival during acute infection. Thus, these studies suggest that iPLA 2 γ plays a cardioprotective role during the acute stage of Chagas' disease.


  • Intranasal Vaccinations with the trans -Sialidase Antigen plus CpG Adjuvant Induce Mucosal Immunity Protective against Conjunctival Trypanosoma cruzi Challenges

    by O. K. Giddings, C. S. Eickhoff, N. L. Sullivan, D. F. Hoft

    Trypanosoma cruzi is an intracellular protozoan parasite capable of infecting through mucosal surfaces. Our laboratory has previously elucidated the anatomical routes of infection after both conjunctival and gastric challenge in mice. We have shown that chronically infected mice develop strong immune responses capable of protecting against subsequent rechallenge with virulent parasites through gastric, conjunctival, and systemic routes of infection. We have also shown that intranasal immunizations with the unique T. cruzi trans -sialidase (TS) antigen protect against gastric and systemic T. cruzi challenge. In the current work we have investigated the ability of purified TS adjuvanted with CpG-containing oligonucleotides to induce immunity against conjunctival T. cruzi challenge. We confirm that intranasal vaccinations with TS plus CpG induce TS-specific T-cell and secretory IgA responses. TS-specific secretory IgA was detectable in the tears of vaccinated mice, the initial body fluid that contacts the parasite during infectious conjunctival exposures. We further show that intranasal vaccinations with TS plus CpG protect against conjunctival T. cruzi challenge, limiting local parasite replication at the site of mucosal invasion and systemic parasite dissemination. We also provide the first direct evidence that mucosal antibodies induced by intranasal TS vaccination can inhibit parasite invasion.


  • Open Access

    Anatomical Route of Invasion and Protective Mucosal Immunity inTrypanosoma cruziConjunctival Infection

    by O. K. Giddings, C. S. Eickhoff, T. J. Smith, L. A. Bryant, D. F. Hoft

    Trypanosoma cruziis a protozoan parasite that can initiate mucosal infection after conjunctival exposure. The anatomical route ofT. cruziinvasion and spread after conjunctival parasite contamination remains poorly characterized. In the present work we have identified the sites of initial invasion and replication after contaminative conjunctival challenges withT. cruzimetacyclic trypomastigotes using a combination of immunohistochemical and real-time PCR confirmatory techniques in 56 mice between 3 and 14 days after challenge. Our results demonstrate that the predominant route of infection involves drainage of parasites through the nasolacrimal duct into the nasal cavity. Initial parasite invasion occurs within the ductal and respiratory epithelia. After successive waves of intracellular replication and cell-to-cell spread, parasites drain via local lymphatic channels to lymph nodes and then disseminate through the blood to distant tissues. This model of conjunctival challenge was used to identify immune responses associated with protection against mucosal infection. Preceding mucosal infection induces mucosal immunity, resulting in at least 50-fold reductions in recoverable tissue parasite DNA in immune mice compared to controls 10 days after conjunctival challenge (P< 0.05). Antigen-specific gamma interferon production by T cells was increased at least 100-fold in cells harvested from immune mice (P< 0.05). Mucosal secretions containingT. cruzi-specific secretory immunoglobulin A harvested from immune mice were shown to protect against mucosal parasite infection (P< 0.05), demonstrating that mucosal antibodies can play a role inT. cruziimmunity. This model provides an important tool for detailed studies of mucosal immunity necessary for the development of mucosal vaccines.


  • Type 1 Immunity Provides Both Optimal Mucosal and Systemic Protection against a Mucosally Invasive, Intracellular Pathogen

    by Daniel F. Hoft, Chris S. Eickhoff

    It has been hypothesized that optimal vaccine immunity against mucosally invasive, intracellular pathogens may require the induction of different types of immune responses in mucosal and systemic lymphoid tissues. Mucosal type 2/3 responses (producing interleukin-4 [IL-4], IL-6 and/or transforming growth factor β) could be necessary for optimal induction of protective secretory immunoglobulin A responses. On the other hand, systemic type 1 responses (including gamma interferon [IFN-γ], tumor necrosis factor alpha, and optimal cytotoxic T-cell responses) are likely to be critical for protection against the disseminated intracellular replication that occurs after mucosal invasion. Despite these predictions, we recently found that vaccines inducing highly polarized type 1 immunity in both mucosal and systemic tissues provided optimal mucosal and systemic protection against the protozoan pathogenTrypanosoma cruzi. To further address this important question in a second model system, we now have studied the capacity of knockout mice to develop protective immune memory.T. cruziinfection followed by nifurtimox treatment rescue was used to immunize CD4, CD8, β2-microglobulin, inducible nitric oxide synthase (iNOS), IL-12, IFN-γ, and IL-4 knockout mice. Despite the previously demonstrated importance of CD4+T cells, CD8+T cells, and nitric oxide forT. cruziimmunity, CD4, CD8, and iNOS knockout mice developed mucosal and systemic protective immunity. However, IL-12, IFN-γ, and β2-microglobulin-deficient mice failed to develop mucosal or systemic protection. In contrast, IL-4 knockout mice developed maximal levels of both mucosal and systemic immune protection. These results strongly confirm our earlier conclusion from studies with polarizing vaccination protocols that type 1 immunity provides optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.


  • Open Access

    Differential Interleukin-8 and Nitric Oxide Production in Epithelial Cells Induced by Mucosally Invasive and NoninvasiveTrypanosoma cruziTrypomastigotes

    by C. S. Eickhoff, L. Eckmann, D. F. Hoft

    Trypanosoma cruzimetacyclic trypomastigotes (MT), but not blood form trypomastigotes (BFT), are highly mucosally infective. We investigated the abilities of MT and BFT to induce inflammation and/or intracellular killing activity within mucosal epithelia. BFT, but not MT, induced marked increases in interleukin-8, GRO-α, MCP-1, and nitric oxide production in HeLa and AGS cells, despite similar infectivities. MT may avoid induction of inflammation as an important biological mechanism facilitating mucosal invasion.


  • Type 1 Immunity Provides Optimal Protection against Both Mucosal and SystemicTrypanosoma cruziChallenges

    by D. F. Hoft, C. S. Eickhoff

    Chagas' disease results from infection withTrypanosoma cruzi, a protozoan parasite that establishes systemic intracellular infection after mucosal invasion. We hypothesized that ideal vaccines for mucosally invasive, intracellular pathogens likeT. cruzishould induce mucosal type 2 immunity for optimal induction of protective secretory immunoglobulin A (IgA) and systemic type 1 immunity protective against intracellular replication. However, differential mucosal and systemic immune memory could be difficult to induce because of reciprocal inhibitory actions between type 1 and type 2 responses. To test our hypotheses, we investigated the protective effects of type 1 and type 2 biased vaccines against mucosal and systemicT. cruzichallenges. Intranasal vaccinations were given with recombinant interleukin-12 (IL-12)- and IL-4-neutralizing antibody (Ab) for type 1 immune bias, or recombinant IL-4 and gamma interferon-neutralizing Ab for type 2 immune bias. Cytokine RNA and protein studies confirmed that highly polarized memory immune responses were induced by our vaccination protocols. Survival after virulent subcutaneousT. cruzichallenge was used to assess systemic protection. Mucosal protection was assessed by measuring the relative inhibition of parasite replication in mucosal tissues early after oralT. cruzichallenge, using both PCR and quantitative culture techniques. As expected, only type 1 responses protected against systemic challenges (P< 0.01). However, contrary to our original hypothesis, type 1 responses optimally protected against mucosal challenges as well (P< 0.05). Type 1 and type 2 biased vaccines induced similar secretory IgA responses. We conclude that future vaccines forT. cruziand possibly other mucosally invasive, intracellular pathogens should induce both mucosal and systemic type 1 immunity.


  • Cruzipain Induces Both Mucosal and Systemic Protection againstTrypanosoma cruziin Mice

    by Anita R. Schnapp, Chris S. Eickhoff, Donata Sizemore, Roy Curtiss, Daniel F. Hoft

    Cruzipain, the major cysteinyl proteinase ofTrypanosoma cruzi, is expressed by all developmental forms and strains of the parasite and stimulates potent humoral and cellular immune responses during infection in both humans and mice. This information suggested that cruzipain could be used to develop an effectiveT. cruzivaccine. To study whether cruzipain-specific T cells could inhibitT. cruziintracellular replication, we generated cruzipain-reactive CD4+Th1 cell lines. These T cells produced large amounts of gamma interferon when cocultured with infected macrophages, resulting in NO production and decreased intracellular parasite replication. To study the protective effects in vivo of cruzipain-specific Th1 responses against systemicT. cruzichallenges, we immunized mice with recombinant cruzipain plus interleukin 12 (IL-12) and a neutralizing anti-IL-4 MAb. These immunized mice developed potent cruzipain-specific memory Th1 cell responses and were significantly protected against normally lethal systemicT. cruzichallenges. Although cruzipain-specific Th1 responses were associated withT. cruziprotective immunity in vitro and in vivo, adoptive transfer of cruzipain-specific Th1 cells alone did not protect BALB/c histocompatible mice, indicating that additional immune mechanisms are important for cruzipain-specific immunity. To study whether cruzipain could induce mucosal immune responses relevant for vaccine development, we prepared recombinant attenuatedSalmonella entericaserovar Typhimurium vaccines expressing cruzipain. BALB/c mice immunized with salmonella expressing cruzipain were significantly protected againstT. cruzimucosal infection. Overall, these data indicate that cruzipain is an importantT. cruzivaccine candidate and that protectiveT. cruzivaccines will need to induce more than CD4+Th1 cells alone.